Collaborators at the Keio and Osaka Universities Present Key Non-Clinical Data with Stable/Functional-Induced Regulatory T Cells (S/F-iTregs) in Autoimmune Disease Models
 |
OSAKA, Japan, May 29, 2023 /PRNewswire/ -- RegCell collaborators from Keio University and Osaka University presented key data at ISID 2023 Tokyo Satellite Meeting. Their presentation demonstrated that in a murine pemphigus model, S/F-iTregs significantly decreased clinical scores, circulating anti-Dsg3 IgG titers, and other autoimmune markers related to Pemphigus. Collaborators also reported that S/F-iTregs generated from samples obtained from patients with Pemphigus also showed potent inhibition of autologous T cell proliferation in vitro.
Pemphigus is a serious and sometimes fatal autoimmune skin disease. RegCell's proprietary platform allows for creating induced antigen-specific regulatory T-cells (Tregs) that are stable in vivo and maintain a high degree of functionality (S/F-iTregs). RegCell was cofounded by Professor Shimon Sakaguchi from Osaka university and Kyoto university, who is credited with the original discovery of Tregs.
Tregs play a central role in managing immune self-tolerance and depleted or dysfunctional Tregs are characteristic of many autoimmune disorders. "There has been interest in using Tregs as a treatment for autoimmune disorders for many years. However, to date, these efforts have been limited by lack of antigen-specificity and persistence. The ability to create stable/functional Treg cells that are antigen-specific has until now been elusive. We believe that RegCell's proprietary platform can accomplish this goal by inducing Tregs from antigen-specific effector T-cells that appear to maintain their functionality, and we look forward to advancing our S/F-iTreg platform into clinical development", said Professor Sakaguchi.
About RegCell
RegCell is a preclinical-stage biotechnology company located in Japan with investment from leading Japanese institutional investors including The University of Tokyo Edge Capital Partners. RegCell is developing S/F-iTregs as a potential treatment for patients with autoimmune disorders and to prevent transplant rejection.
For more information about RegCell please visit https://regcell.jp/en/
Contact: Daisuke Ishikawa, Ph.D. (hpregcell@regcell.jp)
Source: RegCell Co., Ltd.